An expanded access clinical program with ZD1839 (Iressa) [gefitinib] for patients with advanced non-small cell lung cancer
Latest Information Update: 29 Dec 2006
At a glance
- Drugs Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 20 Nov 2006 Status change
- 11 Jul 2006 New trial record.